Antifungal Drugs: Classes, Mechanisms, Clinical Uses and Adverse Effects

Medical education review; updated 10 November 2026. Regimens must be individualized and checked against local guidelines.

Overview

Antifungal selection requires knowing the organism, infection site, severity, host immune status and local susceptibility patterns. Superficial dermatophyte disease differs substantially from candidemia, cryptococcal meningitis and invasive aspergillosis [1–3].

Major drug classes and mechanisms

  • Azoles: fluconazole, itraconazole, voriconazole, posaconazole and isavuconazole inhibit fungal lanosterol 14-alpha-demethylase, reducing ergosterol synthesis. Spectrum differs: fluconazole does not reliably treat Aspergillus and is inactive against several Candida species.
  • Echinocandins: micafungin, caspofungin and anidulafungin inhibit beta-(1,3)-D-glucan synthase, disrupting fungal cell walls. Rezafungin is a longer-acting echinocandin used in specified candidemia/invasive candidiasis indications.
  • Polyenes: amphotericin B binds ergosterol and disrupts fungal membranes; liposomal formulations generally reduce nephrotoxicity compared with conventional amphotericin B.
  • Flucytosine: converted in fungal cells into metabolites that impair RNA/DNA synthesis, typically combined with amphotericin B for cryptococcal meningitis.
  • Allylamines: terbinafine inhibits squalene epoxidase and is important for dermatophyte and nail infections.
  • Griseofulvin: disrupts mitosis and remains useful for certain dermatophyte infections.

Evidence-based treatment examples

For most non-neutropenic adults with candidemia, an echinocandin is the guideline-recommended initial treatment; fluconazole can be an alternative in carefully selected clinically stable patients unlikely to harbor resistance. Repeat blood cultures to document clearance and assess metastatic complications. Uncomplicated candidemia generally requires at least 14 days after bloodstream clearance and resolution of symptoms [1]. For invasive pulmonary aspergillosis, voriconazole is a primary option, with isavuconazole or liposomal amphotericin B alternatives [2]. Superficial tinea may respond to topical treatment, whereas tinea capitis requires systemic treatment [3].

Pharmacokinetics and interactions

Fluconazole is largely renally cleared and may require dose adjustment. Voriconazole exhibits variable CYP-dependent metabolism and often benefits from therapeutic drug monitoring; visual effects, photosensitivity, hepatotoxicity and interactions require attention. Itraconazole absorption depends on formulation and gastric conditions; it can worsen heart failure. Azoles have clinically important CYP interactions and may prolong QT, while isavuconazole shortens QT. Echinocandins are intravenously administered with few CYP interactions, but liver-related monitoring may be needed [1,2].

Toxicity and monitoring

Amphotericin B may cause infusion reactions, hypokalemia, hypomagnesemia and kidney injury: monitor electrolytes and renal function. Flucytosine can cause cytopenias and hepatotoxicity, especially with accumulation in renal impairment; use drug monitoring when available. Oral terbinafine can cause liver injury and taste disturbances. Antifungal susceptibility and species identification are crucial in invasive disease and where resistance is plausible [1–3].

Clinical takeaways

Do not use echinocandin monotherapy for cryptococcal meningitis, fluconazole as empiric treatment for all invasive mould infections, or topical agents alone for tinea capitis. Verify pregnancy considerations, local approval and resistance data for the precise pathogen and drug.

References

  1. Pappas PG, Kauffman CA, Andes DR, et al. Clinical practice guideline for the management of candidiasis: 2016 update by the Infectious Diseases Society of America. Clin Infect Dis. 2016;62(4):e1–e50. doi:10.1093/cid/civ933. Available from: https://doi.org/10.1093/cid/civ933
  2. Patterson TF, Thompson GR 3rd, Denning DW, et al. Practice guidelines for the diagnosis and management of aspergillosis: 2016 update by IDSA. Clin Infect Dis. 2016;63(4):e1–e60. doi:10.1093/cid/ciw326. Available from: https://www.idsociety.org/practice-guideline/aspergillosis
  3. Centers for Disease Control and Prevention. Treating fungal diseases with antifungals. Updated 2026 Oct 26. Available from: https://www.cdc.gov/fungal/treatment/
Medical & AI Disclaimer

The information provided on Sumathi Publications is for general educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare professional regarding any medical condition or treatment decision.

We strive to keep our content accurate and up to date; however, some content may be created or assisted using artificial intelligence (AI) and may contain errors or omissions. All information should be independently verified before use. Reliance on any content provided by Pharmacology Mentor is at your own risk.

Leave a Reply

Your email address will not be published. Required fields are marked *